Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)-Reference-Cited by-同舟云学术

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

Published:1999-04 Issue:8 Volume:57 Page:917-925
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Discafani Carolyn M.,Carroll Marion L.,Floyd M.Brawner,Hollander Irwin J.,Husain Zaheed,Johnson Bernard D.,Kitchen Douglas,May Michael K.,Malo Madhu S.,Minnick Albert A.,Nilakantan Ramaswamy,Shen Ru,Wang Yu-Fen,Wissner Allan,Greenberger Lee M.

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference31 articles.

1. The type 1 (EGFR-related) family of growth factor receptors and their ligands;Prigent;Prog Growth Factor Res,1992

2. Signaling through scaffold, anchoring, and adaptor proteins;Pawson;Science,1997

3. Prevalence of aberrant expression of epidermal growth factor receptor in human cancers;Gullick;Br Med Bull,1991

4. Human breast cancer;Slamon;Science,1987

5. Receptor blockade with monoclonal antibodies as anti-cancer therapy;Baselga;Pharmacol Ther,1994

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the design of small molecular drugs with acrylamides covalent warheads;Bioorganic & Medicinal Chemistry;2024-10

2. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents;Current Medicinal Chemistry;2024-06-10

3. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials;Signal Transduction and Targeted Therapy;2023-09-06

4. Crosstalking interactions between P2X4 and 5-HT3A receptors;Neuropharmacology;2023-09

5. EGFR is a potential dual molecular target for cancer and Alzheimer’s disease;Frontiers in Pharmacology;2023-08-02